Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab versus ranibizumab for exudative age-related macular degeneration
NL-OMON21233Active, not recruiting
- Sponsor
- Prof. Dr. R.O. Schlingemann Department of Ophthalmology, Room A2-122 Academisch Medisch Centrum Meibergdreef 9 1105 AZ Amsterdam Tel +31205663616 e-mail: [email protected]
- Start
- Jan 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in age-related macular degeneration (AMD) and Subretinal neovascularization comparing Avastin monthly intravitreal injection with Lucentis monthly intravitreal injection (2 arms). Primary endpoint: Change in best-corrected visual acuity. Started Jan 2009; status: active, not recruiting.
02
Drugs
bevacizumabranibizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on NL-OMON21233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21233.